-
Rapamycin in T-Cell Immunometabolism
2026-09-26
Rapamycin (Sirolimus) offers a direct way to perturb mTOR signaling, but its effects in immune assays depend on the cell population and functional endpoint. This article examines a study combining glycolysis inhibition with rapamycin to show how T-cell metabolism can change keratinocyte injury in oral lichen planus models.
-
In Vitro Protocols for Mammalian Embryonic Dormancy
2026-09-26
This Nature Protocols article describes noninvasive, in vitro methods for inducing and reversing a diapause-like dormant state in mouse blastocysts, human blastoids, and pluripotent stem cells through mTOR inhibition. The workflows make dormancy research more accessible and scalable while emphasizing that model-specific validation and careful assessment of reversibility remain essential.
-
Taltirelin Protects Dopaminergic Neurons in PD Models
2026-09-25
Zheng and colleagues found that Taltirelin reduced toxin-associated oxidative stress and cell death in neuronal models and improved motor performance while preserving nigral dopaminergic neurons in two mouse models of Parkinson’s disease. The study links these effects to lower MAO-B activity and reduced pathological tau and α-synuclein cleavage, providing a preclinical rationale for further testing rather than evidence of clinical disease modification.
-
mCherry mRNA as an Expression-Control Tool
2026-09-25
Learn how mCherry mRNA can help separate delivery and translation effects from biological reporter signals. This article connects the R1017 reporter to assay-design lessons from a bacterial NADH/NAD+ biosensor study—while clarifying where the two approaches differ.
-
Dihydroartemisinin: Translational Research Beyond the Label
2026-09-24
A translational framework for studying Dihydroartemisinin across malaria, mTOR signaling, and inflammation research—without confusing a compound’s reputation with evidence for a specific mechanism.
-
Bazedoxifene Workflows for ER and IL-6 Research
2026-09-24
Use Bazedoxifene to distinguish estrogen-receptor pharmacology from emerging IL-6/GP130 signaling effects in cell-based research. This practical guide combines setup choices, assay parameters, and troubleshooting while keeping osteoporosis models and exploratory cancer studies in their appropriate evidence contexts.
-
In Vitro mTOR Inhibition for Embryonic Dormancy
2026-09-23
This Nature Protocols article presents reproducible in vitro workflows for placing mouse and human early embryonic models into a reversible, diapause-like dormant state through pharmacological mTOR inhibition. Its main practical contribution is a noninvasive framework for comparing dormancy across blastocysts, blastoids, and pluripotent stem cells while defining readouts for state maintenance and reactivation.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-22
AZD8055 provides a selective ATP-competitive approach for investigating mTORC1 and mTORC2 signaling in biochemical, cellular, and animal research. It is best used for controlled mechanistic studies rather than clinical efficacy conclusions or experiments requiring a water-soluble compound.
-
Rapamycin (Sirolimus): mTOR Workflow Guide
2026-09-22
Build reproducible Rapamycin assays for mTOR signaling, proliferation, apoptosis, and immunosuppression research. This guide also translates emerging gut-microbiota findings into practical exposure, stability, and donor-resolved experimental workflows.
-
MLN4924: Reliable Neddylation Assay Design
2026-09-21
This scenario-driven guide explains how MLN4924 (SKU B1036) can help researchers connect NAE inhibition with cell-cycle, viability, and protein-degradation readouts. It covers mechanism, assay compatibility, stock preparation, interpretation, and practical supplier-selection criteria supported by product data and recent neddylation research.
-
MMAE in ADC Research: From Payload to Assay Design
2026-09-21
Monomethyl auristatin E (MMAE) is more than a potent cytotoxin: it is a useful reference for separating payload activity from tumor-cell state and delivery biology. This article connects MMAE assay design with mechanistic insights from EBV-driven nasopharyngeal carcinoma research.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-20
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling in cancer and metabolic models. It is useful for mechanistic preclinical work, but its water insolubility, solution stability requirements, and limited clinical benefit make it unsuitable for direct clinical efficacy conclusions.
-
NAD+ Workflows for Energy-Stress Research
2026-09-19
Build more informative redox, enzyme, and energy-stress experiments with Nicotinamide Adenine Dinucleotide (NAD+). This practical guide connects NAD+ handling and assay design to the revised AMPK–ULK1 model, helping researchers distinguish redox effects from autophagy-specific signaling.
-
Torin2: A Causal Framework for mTOR Cell-Death Assays
2026-09-19
Torin2 is a potent mTOR inhibitor for dissecting how pathway inhibition produces cancer-cell death. This article presents a causal assay framework inspired by recent Pol II degradation research, helping distinguish transcriptional collapse, cytotoxicity, and migration effects.
-
MK-2206 Dihydrochloride: Akt Assay Workflows
2026-09-18
Build more informative Akt studies with MK-2206 dihydrochloride, from concentration-response and apoptosis assays to pathway-linked metabolic experiments. This guide connects selective Akt inhibition with the Wnt–O-GlcNAcylation findings reported in bone biology while emphasizing practical controls, formulation, and troubleshooting.